Understanding Gastroenterology Adherence Through Real-World Data

Gastrointestinal conditions affect millions of patients worldwide and often require long-term treatment to manage symptoms. Even the most effective therapies can only deliver results when patients remain engaged with treatment over time.

For pharmaceutical organizations, improving adherence represents one of the greatest opportunities to maximize therapeutic outcomes. However, many adherence strategies are built on a common misconception: patients only miss doses because they forget.

After analyzing 130+ behavioral signals per patient, Medisafe identified predictable behavioral patterns that influence whether patients stay engaged with therapy over time. The findings reveal that long-term patient persistence isn’t shaped by forgetfulness, but rather a combination of behavioral, environmental, and treatment-related factors

Gastroenterology Adherence Follows Behavioral Patterns

Across gastroenterology patient populations, Medisafe's analysis uncovered several notable trends:

• Adherence rates vary across countries and regions.
• Dosage fluctuates throughout the week, with adherence rates varying by day and time of day.
• Different GI diagnoses demonstrate distinct adherence patterns and support needs.
• Patients miss doses due to perceived lack of need, side effect concerns, and other behavioral factors.

These patterns reveal that predictable behavioral signals can be identified and addressed through more personalized, effective interventions, reinforcing a critical reality: adherence challenges are driven by the day-to-day complexities of managing a chronic GI condition, not simply memory lapses.

‍

Why Adherence Requires More Than Reminders

Many patient support programs rely on static reminders and generalized outreach. While these approaches can provide value, they often fail to account for the dynamic nature of patient behavior.

A patient managing Crohn's disease faces different therapy barriers than someone living with irritable bowel syndrome. Likewise, a patient who struggles with weekend routine disruptions requires different support than someone whose adherence declines later in the day.

Without visibility into these behavioral patterns, support programs often intervene too late or deliver engagement that does not align with a patient's actual needs.

Turning Behavioral Intelligence Into Better Outcomes

Built on +12 years of real-world patient behavior data, Medisafe’s engagement engine helps pharmaceutical organizations identify risk before therapy abandonment occurs.

By analyzing therapy-specific behavioral signals, treatment symptoms, and real-world patient activity, Medisafe enables brands to deliver personalized support at the moments when intervention has the greatest impact.

The result is stronger patient engagement, improved adherence, and greater long-term value across gastroenterology portfolios.

New Insights Into Gastroenterology Patient Behavior

Medisafe's latest gastroenterology adherence analysis explores how geography, daily routines, diagnosis type, and behavioral factors influence long-term persistence.

The findings offer pharmaceutical teams practical insights into the drivers of GI adherence and actionable opportunities to strengthen patient support programs.

‍